Skip to content



Tarcocimab tedromer
Once every month

Compared to:

Once every 2 months after 3 monthly doses

About the DAYLIGHT Study in Wet AMD

The Phase 3 DAYLIGHT study is a global, multi-center, randomized pivotal study designed to evaluate the efficacy and safety of high-frequency tarcocimab tedromer in patients with treatment-naïve wet AMD. Patients are randomized to receive either tarcocimab tedromer on a monthly dosing regimen or to receive standard-of-care aflibercept on a fixed dosing regimen of every 8-weeks after three monthly loading doses per its label. The DAYLIGHT study is intended to clarify the efficacy of tarcocimab tedromer to treat high need patients with wet AMD and, if successful, is intended to serve as the basis for approval in wet AMD with monthly dosing. Consistent with this intent to serve as an approval study, we are extending the length of DAYLIGHT, specifically extending the primary endpoint to the average of weeks 40, 44 and 48. DAYLIGHT has completed enrollment of approximately 550 patients worldwide. Additional information about the DAYLIGHT study (also called Study KS301P107) can be found on under Trial Identifier NCT04964089 (